Charleston Laboratories, Inc

Quick facts

Marketed products

• Vicoprofen · Other

Phase 3 pipeline

• CL-108 · Pain management
  CL-108 is a novel, orally administered, non-opioid, non-sedating, and non-addictive analgesic.

Phase 2 pipeline

• Arm 1: CL-H1T · Pain
  CL-H1T is a compound that targets the kappa opioid receptor.

Phase 1 pipeline

• M366

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Charleston Laboratories, Inc portfolio CI brief
• Charleston Laboratories, Inc pipeline updates RSS